Background/Aims: MicroRNA-9 (miR-9) is involved in inflammatory reaction in atherosclerosis; however, its function and regulatory mechanisms remain unclear. We aimed to uncover the exact roles of miR-9 and downstream signaling pathways using in vitro human atherosclerosis models. Methods: We used oxidized low-density lipoprotein (oxLDL)-stimulated human THP-1 derived macrophages, oxLDL-stimulated human primary peripheral blood monocytes and lipopolysaccharides (LPS) or Alum-stimulated human THP-1 derived macrophages as in vitro atherosclerosis inflammation models. Transient transfection of over-expression vectors, small interference RNAs (siRNAs) or antisense oligonucleotides was used to regulate intracellular protein or miR-9 levels. Cell responses and signal transduction were detected by multiple assays including Western blotting, enzyme-linked immunosorbent assay (ELISA) and luciferase reporter assay. Results: MiR-9 inhibited while anti-miR-9 antisense oligonucleotides induced interleukin-1 beta (IL-1β) and NLRP3 inflammasome activation in all in vitro models. Janus kinase 1 (JAK1) and matrix metalloproteinase 13 (MMP-13) were identified as the target genes of miR-9. In oxLDL-stimulated human THP-1 derived macrophages, knockdown of JAK1 by siRNA blocked the phosphorylation of signal transducer and activator of transcription 1 (STAT1) and mimicked the effects of miR-9. In the same model, JAK1 knockdown blocked the phosphorylation of NF-κB p65 in the nuclei and the phosphorylation of NF-κB IκBα in the cytoplasm. Conclusions: Our study demonstrated that miR-9 could inhibit activation of the NLRP3 inflammasome and attenuate atherosclerosis-related inflammation, likely through the JAK1/STAT1 signaling pathway. Therefore, miR-9 may serve as a potential therapeutic target for atherosclerosis.
MicroRNA-9 Inhibits NLRP3 Inflammasome Activation in Human Atherosclerosis

Introduction
Atherosclerosis is one of the leading causes of death in vascular diseases. Although the etiopathogenesis is not completely clear, atherosclerosis has been recognized as a complex chronic inflammatory disease, in which continuous dyslipidemia and inflammation play a vital role [1, 2] . Atherosclerosis-related inflammation is elicited by atherogenic lipid mediators, especially oxLDL. Upon oxLDL stimulation, monocytes from peripheral blood migrate to the subendothelial space, where they differentiate into macrophages. Activated macrophages secrete various proinflammatory mediators, including interferon γ (IFN-γ), interleukins (IL), and proteases, leading to the inflammatory cascade and contributing to unlimited lipid uptake, foam cell formation and progression of atherosclerosis [3] [4] [5] [6] .
The NLRP3 inflammasome was identified as a novel link between cholesterol metabolism and inflammation [7, 8] . It belongs to the nucleotide oligomerization domain (NOD)-like receptors (NLRs) family, which has been closely implicated in the pathogenesis of several chronic inflammatory diseases, including atherosclerosis, gout, and type 2 diabetes [9] . The NLRP3 receptor responds to numerous diverse exogenous and endogenous ligands, including bacteria [10] , extracellular ATP [11] , amyloid-β [12] , uric acid [13] , and cholesterol crystals [7] . In a recent study, oxLDL has also been proved to activate the NLRP3 inflammasome [14] . Once activated, NLRP3 receptor recruits the adaptor protein ASC (apoptosis-associated speck like protein containing a caspase-recruitment domain) and procaspase-1 to form an active NLRP3 inflammasome complex [15] , which results in caspase-1 activation and subsequent cleavage of IL-1β and IL-18 into their active forms. Recently, inhibition of the NLRP3 inflammasome has been shown to protect against atherosclerosis [16, 17] . However, its mechanisms and related signaling pathways have not been clarified.
MicroRNAs (miRNAs) are a family of small noncoding RNAs with 20-25 nucleotides, which function through binding to their complementary sites on the 3'-UTR of target mRNAs to mediate mRNA degradation and translation repression [18] . MiRNAs function in various biological and pathological processes, including atherosclerosis and inflammation [19] [20] [21] [22] . Previous report indicated that microRNAs played a key role in macrophage biology by regulating their differentiation from precursor cells and modulating the expression of inflammatory mediators and signaling pathways [23] . We also found that several miRNAs were highly expressed in human peripheral blood monocytes stimulated with oxLDL [24] . Among them, miR-146a and miR-155 have been reported to regulate atherosclerosisrelated inflammation [25] . However, whether and how miR-9 regulates inflammation in atherosclerosis is still unknown. In this study, we aimed to investigate the effects and mechanisms of miR-9 on the NLRP3 inflammasome in oxLDL-stimulated human THP-1 derived macrophages and human primary monocytes from peripheral blood.
Materials and Methods
Cell culture
Human monocytic cell line THP-1 (American Type Culture Collection, Bethesda, MD, USA) was cultured in RPMI 1640 medium (Gibco, NY, USA) supplemented with 10% fetal bovine serum (FBS),10 mmol/L HEPES (Sigma, St Louis, MO, USA) and 100 U/mL penicillin-streptomycin (Sigma). To induce the differentiation of monocytes into macrophages, we cultured human THP-1 cells in 100 nmol/L phorbol12-myristate 13-acetate (Calbiochem, San Diego, CA, USA) for 48 h. The culture medium was then changed into RPMI1640 medium containing 0.5% FBS for a 6 h starvation [26, 27] . For NLRP3 inflammasome stimulation, human THP-1 derived macrophages were treated with 50 μg/mL oxLDL for 24 h (4 h for STAT1 signaling experiments), 100 ng/mL LPS (Escherichia coli serotype O111:B4, Sigma) for 24 h or 130 µg/mL Aluminium Hydrogel (Alum, from Sigma) for 4 h [28, 29] .
Peripheral human blood was obtained from healthy donors. This study conformed to the principles outlined in the Declaration of Helsinki for use of human blood and was approved by the Ethics Committee of Experimental Research, Medical College, Shanghai Jiaotong University. Human primary peripheral blood monocytes were prepared as previously described [24] . Briefly, peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-isopaque (Sigma) density gradient. PBMCs were seeded in six-well plates using RPMI1640 medium containing 5% autologous serum. After 2 h incubation in 5% CO 2 at 37℃, nonadherent cells in medium were carefully removed and attached cells were human primary peripheral blood monocytes. Human primary peripheral blood monocytes were stimulated with 100 ng/mL LPS for 24h.
Transfection of miR-9 precursor and inhibitor MiR-9 precursor (pre-miR-9) or miR-9 inhibitor (anti-miR-9) (Ambion) was transfected into human THP-1 derived macrophages and human primary peripheral blood monocytes using the fast transfection protocol recommended by Qiagen (USA). The miR-9 precursor or inhibitor was diluted in the medium to a final concentration of 50 nM. To confirm the efficiency of transfection, the same amount of Cy3-labelled negative control (Ambion) was also transfected. Six hours after transfection, the cells were exposed to oxLDL (50 μg/mL) for another 24 h and then harvested for further experiments.
Real-time PCR
Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction. RNA was reversely transcribed using GoTaq® 2-Step RT-qPCR System (Promega, Madison, WI, USA) [30] . Real-time PCR was performed in triplicates using a Roche LightCycler 480 system. β-actin was used as an endogenous control. The primers for IL-1β, NLRP3, JAK1, MMP13 and β-actin were designed and synthesized by Sangon Biotech, Shanghai, China. The sequences are in Table 1 .
Western blotting assays
Cell culture medium was concentrated using Vivaspin 6 centrifugal concentrator with a 5 kDa cut-off (Sartorius), after which immunoblot analysis was performed. Protein isolation and Western bolt analysis of cell lysates were performed as described previously [11] . Briefly, protein extracts were prepared and protein concentrations were measured using the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA). After denaturation, the solubilized proteins (20 μg) were subjected to electrophoresis on 10% polyacrylamide sodium dodecyl sulphate gels and subsequently transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The membranes were then probed with primary antibodies for IL-1β, pro-IL-1β, pro-caspase-1 , JAK1, MMP-13, and caspase-1 (all from R&D Systems), NLRP3, phospho-p65, IκBα, phospho-STAT1, total STAT1, lamin B, and β-actin (all from Cell Signaling Technology). Secondary goat anti-rabbit or goat-anti-mouse antibodies labeled with far-red fluorescent Alexa Fluor 680 dye were used. Signal detection was performed by Odyssey (Li-cor, USA) [24] . Quantity One (Bio-Rad) was used for scanning and densitometric analysis.
Nuclear and cytoplasmic protein fractionation was performed with the Nuclear/Cytoplasmic Protein Extraction Kit (Beyotime, China) according to the manufacturer's instructions.
To detect the protein level of secreted IL-1β, human THP-1 derived macrophages or human primary peripheral blood monocytes were stimulated, as described, but in the absence of FCS. Cell culture supernatants were harvested and concentrated 10 folds with Ultracel 10K Amicon Ultra centrifugal filters (Merck Millipore, Darmstadt, Germany) [31] . Enzyme-linked immunosorbent assay IL-1β, TGF-β1, MCP-1, and IL-10 ELISA assay kits were purchased from R&D Systems. The concentrations of the secreted IL-1β, TGF-β1, MCP-1, and IL-10 in the human THP-1 derived macrophage or human primary peripheral blood monocyte culture medium were assessed according to the manufacturer's instructions.
DNA construct and luciferase report assay
For luciferase reporter experiments, the 3'UTR of JAK1 and MMP-13 was amplified by PCR from human genomic DNA and cloned into the psiCHECKTM-2 firefly luciferase vector (Promega) between the Not1 and Sgf1 sites. The construct with mutated targeting fragment at the 3'UTR of JAK1 or MMP-13 without the putative miR-9 binding sequence was used as a negative control. The mutant form was synthesized and inserted into the psiCHECKTM-2 firefly luciferase vector. Human THP-1 derived macrophages were seeded into 24-well plates and transfected by using Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen). Cells treated with 10 nM pre-miR-9 or pre-negative control (pre-NC), or with 10 nM antimiR-9 or anti-negative control (anti-NC) (Ambion) were transfected with 0.1 μg of JAK1 or MMP-13 3'UTR firefly luciferase report vector and 0.02 μgp RL-TK Renilla luciferase vector (Promega) for normalization of transfection. After 48 h, cells were washed and lysed by the lysis buffer, and firefly and renilla luciferase activity was determined using the dual-luciferase reporter assay system and a luminometer (Promega) as described previously [32] . Relative reporter activity was obtained by normalizing the firefly luciferase activity to the internal control renilla luciferase activity.
SiRNA JAK1 small interference RNA (siRNAs) and siRNA negative control non-silencing siRNA were procured from Genepharma (Shanghai, China). Three individually designed siRNAs for JAK1 were used for this study. 
Statistical analysis
Data were presented as mean ± SEM of three independent experiments. Two-tailed Student's t test was performed for all comparisons between two groups. One-way ANOVA was performed when three or more groups were compared.
Results
MiR-9 inhibits IL-1β expression and NLRP3 inflammasome activation in oxLDL-stimulated human THP-1 derived macrophages
Initially, we confirmed that oxLDL elicited IL-1β expression and release in human THP-1 derived macrophages by Western blotting assays, real-time PCR and ELISA. The levels of both the active form of IL-1β (IL-1β p17) in cell culture medium and the precursor form of IL-1β(pro-IL-1β p31) in cell lysates were elevated (Fig. 1A) . By contrast, pre-miR-9 pretreatment mitigated both the active and precursor form of IL-1β (versus miRNA negative control, pre-NC, p<0.05), while miR-9 inhibitor (anti-mir-9, an antisense oligonucleotide blocking mir-9 expression) pretreatment increased both the active and precursor form of IL-1β (versus miRNA inhibitor negative control, anti-NC, p<0.05) (Fig. 1 A) . ELISA also showed that pre-miR-9 decreased, while miR-9 inhibitor increased IL-1β release ( Fig. 1 C) . A consistent trend was observed in the mRNA level of IL-1β (Fig. 1D ). All these methods verified that miR-9 inhibited IL-1β expression and secretion. The cleavage of IL-1β is mediated by caspase-1, a proenzyme (45 kDa) which is autoproteolytically cleaved into active10 kDa and 20 kDa forms upon activation ofthe inflammasome [12] . We further detected the active form of caspase-1 by Western blotting assays. As demonstrated in Fig. 1A , oxLDL significantly enhanced the levels of active caspase-1 (caspase-1 p10). Pre-miR-9 mitigated oxLDL-induced activation of caspase-1 (versus pre-NC, p<0.05), whereas miR-9 inhibitor elevated the levels of active caspase-1. However, there was no significant difference in pro-caspase-1 levels among all groups ( Fig. 1 A) . This data suggests that miR-9 inhibits caspase-1 activation in oxLDL-stimulated human THP-1 derived macrophages.
The NLRP3 inflammasome signaling pathway is well-known to regulate caspase-1 activation and subsequent cleavage of IL-1β. We further determined the protein and mRNA levels of NLRP3 in oxLDL-stimulated human THP-1 derived macrophages. As shown in Fig.  1 A, pre-incubation of pre-miR-9 prior to the addition of oxLDL significantly decreased both the protein and mRNA levels of NLRP3 compared with the negative control group (pre-NC). On the other hand, pre-incubation of miR-9 inhibitor prior to the addition of oxLDL resulted in elevated protein and mRNA levels of NLRP3 (versus anti-NC, p<0.05). These findings suggest that miR-9 inhibits NLRP3 inflammasome activation, which leads to less caspase-1 activation and reduced IL-1β secretion.
We also tested the impact of miR-9 on the secretion of other inflammatory factors by ELISA. As shown in Fig. 1 B, pre-miR-9 pretreatment significantly decreased IL-6 and IL-10 Fig. 1 . MiR-9 inhibits IL-1β expression and NLRP3 inflammasome activation in oxLDL-stimulated human THP-1 derived macrophages. Human THP-1 derived macrophages were pretreated with miR-9 precursor or miR-9 inhibitor and then stimulated with oxLDL. The active form of IL-1β (IL-1β p17) and the active form of caspase-1 (caspase-1 p10) in cell culture medium, and the precursor form of IL-1β, pro-caspase-1, and NLRP3 in cell lysates were determined by Western blotting assays (A). IL-1β secretion was measured by ELISA (C) and mRNA level of IL-1β was measured by real-time PCR (D). The secretion of inflammatory factors (IL-6, IL-10 and TNF-α) was measured by ELISA (B). The mRNA level of NLRP3 was measured by real time PCR (E). Data are shown as mean ± SEM of at least three independent experiments (*P<0.05, 2-tailed Student's t test). protein level in the culture supernatant, which was increased by oxLDL stimulation (versus pre-NC, p<0.05). Compared to the anti-NC group, the anti-miR-9 group showed an increase in IL-6 and IL-10 protein levels (versus anti-NC, p<0.05). The secretion of TNF-α was not affected by pre-mir-9 or anti-mir-9 treatment (Fig. 1 B) . . JAK1 and MMP-13 are miR-9 targets. Human THP-1 derived macrophages were transfected with miR-9 precursor (pre-miR-9), miR-9 inhibitor (anti-miR-9) or their negative control (NC), the protein level of JAK1 and MMP-13 was determined by Western blotting assays (A-C), and the mRNA levels of JAK1 and MMP-13 were determined by real-time PCR (D-E). The firefly luciferase reporter vectors containing wt 3'UTR or mut 3'UTR for either JAK1 or MMP-13 were transfected into human THP-1 derived macrophages together with a constitutively active renilla luciferase vector. Upon treatment of pre-miR-9 or anti-miR-9, and luciferase reporter assay for JAK1 (F) or MMP-13 (G) was performed. Renilla luciferase activity was used a control for transfection efficiency. (*P<0.05, 2-tailed Student's t test).
modulate miR-9 level. As expected, pre-miR-9 inhibited, whereas miR-9 inhibitor promoted firefly luciferase activity in human THP-1 derived macrophages transfected with a JAK1 wt 3'UTR reporter vector (Fig. 3F) . However, this effect was abolished in cells transfected with JAK1 mut 3'UTR vector, a reporter vector containing mutated JAK1 3'UTR for miR-9 binding site (Fig. 3F) , suggesting that JAK1 is a direct target of miR-9 in human THP-1 derived macrophages. Using the same approach, we showed that MMP-13 was also a direct target of miR-9 in human THP-1 derived macrophages (Fig. 3G) .
JAK1 siRNA inhibits IL-1β release and NLRP3 activation in oxLDL-stimulated human THP-1 derived macrophages
To investigate the role of JAK1 in NLRP3 signaling, we designed siRNAs to knock down JAK1 expression in human THP-1 derived macrophages. The knockdown efficiency of JAK1 was tested by real time PCR and Western blotting assays. As shown in Fig. 4A, 24 h after transfection, the JAK1 mRNA level in human THP-1 derived macrophages treated with JAK1 specific siRNA dropped to 14% compared to control. Forty-eight hours after transfection, cells transfected with JAK1 siRNA remained low for JAK1 mRNA (19% versus control). To detect the effect of JAK1 on IL-1β expression, we transfected human THP-1 derived macrophages with JAK siRNA or control siRNA, and stimulated the macrophages with oxLDL for 24 h. As shown in Fig. 4B by Western blotting assays, the active form of IL-1β induced by oxLDL was attenuated in the presence of JAK1 siRNA, but not by control siRNA. In addition, the precursor level of IL-1β was also significantly decreased in the JAK1 siRNA group, but not in the control siRNA group (Fig. 4B) . A similar pattern was observed in IL-1β mRNA levels in the presence of JAK1 siRNA or control siRNA (Fig. 4D) . Consistently, JAK1 siRNA significantly inhibited the release of IL-1β compared with control siRNA (Fig. 4C) .
We further examined the mRNA and protein level of NLRP3 and caspase-1 in oxLDLstimulated human THP-1 derived macrophages. As shown in Fig. 4E , NLRP3 mRNA expression was significantly down-regulated in the JAK1 siRNA group compared with that in the control siRNA group. Consistently, NLRP3 protein level was also down-regulated in the JAK1 siRNA group compared with the control siRNA group (Fig. 4B) . In addition, JAK1 siRNA treatment prior to the addition of oxLDL resulted in reduced levels of active caspase-1 in the culture medium compared with that in the control siRNA group (Fig.4 B) . However, there was no significant difference in pro-caspase-1 expression levels among all groups (Fig.  4B) . Overall, these findings suggest that JAK1 siRNA inhibits the activation of the NLRP3 inflammasome.
To explore whether STAT1 is a downstream effector of JAK1, we transfected human THP-1 derived macrophages with JAK1 siRNA or control siRNA, followed by stimulation with oxLDL for 4 h [33] . Phosphorylated STAT1 levels in the nuclei and total STAT1 levels in the cell were detected by Western blotting assays. As shown in Fig. 5A , B, oxLDL significantly enhanced the levels of phosphorylated STAT1 and total STAT1 compared with the negative control group. The addition of JAK1 siRNA to oxLDL treated cells significantly decreased the phosphorylated STAT1 level compared with the same cells receiving negative control siRNA NC-siRNA. The total STAT1 level was slightly decreased by JAK1 siRNA (Fig. 5A, B) .
JAK1 knockdown abolishes the induction of IL-1β and NLRP3 caused by anti-miR-9
OxLDL is the most important inflammatory stimulus in the pathogenesis of atherosclerosis. OxLdL could induce a series of inflammatory signaling pathways which lead to NLRP3 inflammasome activation in human THP-1 derived macrophages. To further explore the role of JAK1 in oxLDL-stimulated NLRP3 activation, we knocked down JAK1 with siRNA in human THP-1 derived macrophages treated with anti-miR-9, an antisense oligonucleotides that blocked miR-9 expression. We first observed that anti-miR-9 dramatically increased protein expression of IL-1β p17. However, if we also knocked down JAK1 by siRNA along with anti-miR-9 treatment, the protein expression of IL-1βp17 was significantly lower compared to cells receiving only anti-miR-9 but not JAK1 siRNA (Fig. 6A,  B) . There was no significant difference in IL-1β p17 protein expression level between cells receiving anti-miR-9 only and cells receiving both anti-miR-9 and control siRNA. There was also no significant difference in IL-1β p17 protein levels between cells stimulated by oxLDL with or without anti-NC, which did not block miR-9 expression. The protein expression of NLRP3 had a similar pattern to that of IL-1β p17. Anti-miR-9 enhanced NLRP3 expression, which, however, was blocked by JAK1 siRNA (Fig. 6A, C) . Again, this inhibition of anti-miR-9 induced NLRP3 expression was not seen with control siRNA. Negative control miRNA anti-NC also did not change NLRP3 expression level in oxLDLstimulated human THP-1 derived macrophages.
JAK1 siRNA inhibits NF-κB activation in oxLDL-stimulated human THP-derived macrophages oxLDL was reported to activate NF-κB in human THP-1 cells. IL-1β is one of NF-κB target genes, which would be upregulated when NF-κB signaling pathway is activated. We used JAK1 siRNA to test whether JAK1 was involved in oxLDL stimulated NF-κB activation. As shown in Fig. 5 A and D 6 h after oxLdL addition the level of phospho-IκBα increased dramatically in cytoplasm while the expression of p65 increased dramatically in nuclei, indicating activation of NF-κB signaling pathway by oxLDL inhuman THP-1 derived macrophages, which was consistent with previous literature. This activation of NF-κB signaling pathway by oxLDL was inhibited by JAK1 siRNA shown by dramatically decreased phospho-IκBα in cytoplasm and p65 in nuclei (Fig. 5 A,D . The effective fractionation of nuclear and cytoplasmic proteins was 
MiR-9 inhibits IL-1β and NLRP3 expression in LPS-stimulated human THP-1 derived macrophages
LPS is a classic inflammatory stimulus and has been reported to activate the NLRP3 inflammasome [26, 27, 34] . To explore the effect of miR-9 in LPS-stimulated human THP-1 derived macrophages, we examined by Western blotting assays the expression of IL-1β and NLRP3, two key proteins in NLRP3 inflammasome activation. Consistent with previous reports, the addition of LPS dramatically upregulated the expression of IL-1β, which was further elevated by anti-mir-9. In contrast, pre-mir-9 dramatically suppressed LPS-induced IL-1β expression (Fig. 7A, C) . All results were statistically significant. Consistent with literature, LPS greatly upregulated NLRP3 expression in human THP-1 derived macrophages. This induction could be further enhanced by anti-mir-9, but blocked by pre-mir-9. All results were statistically significant (Fig. 7A, C) .
MiR-9 inhibits IL-1β and NLRP3 expression in Alum-stimulated human THP-1 derived macrophages
Alum has been reported as one of the stimuli of the NLRP3 inflammasome [28] . We also tested the effects of miR-9 on expression of IL-1β and NLRP3 in Alum-stimulated human THP-1 derived macrophages. Consistent with previous findings, the addition of Alum dramatically upregulated the expression of IL-1β, which was further elevated by anti-mir-9. In contrast, pre-mir-9 dramatically suppressed Alum induced IL-1β expression (Fig. 8) . All results were statistically significant.
Consistent with literature, Alum greatly upregulated NLRP3 expression in human THP-1 derived macrophages. This induction was further enhanced by anti-mir-9, but blocked by pre-mir-9. All results were statistically significant (Fig. 8) .
MiR-9 inhibits IL-1β and NLRP3 expression in oxLDL-stimulated human primary peripheral blood monocytes
We also explored the effect of mir-9 in oxLDL stimulated human primary peripheral blood monocytes and found similar results as in human THP-1 derived macrophages. oxLDL treatment dramatically induced IL-1β expression in human primary peripheral blood Fig. 8 . Mir-9 inhibits NLRP3 inflammasome activation induced by Alum in human THP-1 derived macrophages. Human THP-1 derived macrophages were pretreated with miR-9 precursor or miR-9 inhibitor and then stimulated with 130 µg/mL Alum for 4 h. IL-1β protein levels in the supernatant and NLRP3 protein levels in total cell lysates were measured by Western blotting assays. Data are shown as mean ± SEM. The data shown are representative of three independent experiments (*P<0
monocytes. When we added anti-mir-9 along with oxLDL, the expression of IL-1β was further upregulated. On the other side, pre-mir-9 which increased mir-9 expression inhibited the upregulation of IL-1β expression induced by oxLDL. All results were statistically significant (Fig. 7B, D) The addition of oxLDL also increased NLRP3 expression in human primary peripheral blood monocytes. Again, this increase was further boosted by anti-mir-9, but reduced by pre-mir-9. All results were statistically significant (Fig. 7B, D) .
Discussion
MiRNAs have been reported to be involved in inflammatory process of atherosclerosis [19] [20] [21] [22] . However, little is known about miR-9, a highly conserved miRNA, which was originally thought to be predominantly expressed in the central nerve system in embryo development [35] . Later, miR-9 was also found to be expressed in other cell types including macrophages [36] , neutrophils [36] , and tumor cells [37] . Our previous study revealed that miR-9 mRNA expression is obviously increased in oxLDL-stimulated human primary peripheral blood monocytes [24] . One important question is whether the increased miR-9 expression works as an inflammation regulator or just a result of inflammation reaction. In the present study, we further explored the effect of miR-9 on oxLDL-stimulated human THP-1 derived macrophages and human primary peripheral blood monocytes. Our data demonstrated for the first time that miR-9 inhibited activation of the NLPR3 inflammasome in these two cell models and JAK1 was one of the miR-9 target genes. Through targeting the JAK1/STAT1 signaling pathway, miR-9 decreased IL-1β expression, caspase-1 activation, and NLRP3 expression. MiR-9 inhibited the secretion of inflammatory factors and NF-κB activation in oxLDL-stimulated human THP-1 derived macrophages. It also inhibited IL-1β and NLPR3 expression in LPS or Alum-stimulated human THP-1 derived macrophages. We also found another miR-9 target gene MMP-13, which plays a vital role in the regulation and organization of collagen in atherosclerotic plaques [33] .
MiR-9 has been reported to play important roles in inflammatory response [36] , immune regulation [36] , lipid uptake [38] , neuron differentiation [39] , and many kinds of tumors [40] . Our results indicate potential anti-inflammatory effects and inhibition of NLRP3 inflammasome by mir-9. There is little study of interaction of mir-9 and inflammasome. Mir-9 was reported to suppress activation of the NLRP3 inflammasome in cardiomyocytes. Through regulating its target gene ELAVL1, mir-9 inhibited hyperglycemiainduced pyroptosis (cardiac cell death) in human ventricular cardiomyocytes. ELAVL1 knockdown abrogates TNF-α induced canonical pyroptosis via NLRP3, caspase-1 and IL-1β suppression [40] . Over-expression of miR-9 in isolated human chondrocytes reduced IL-1β-induced TNF-α production and inhibited MMP-13 in human chondrocytes [41] . We found that mir-9 inhibited the expression of proinflammatory cytokines IL-6 and IL-10 in oxLDL stimulated human THP-1 derived macrophages. The secretion of TNF-α was not affected by increased or decreased mir-9 expression. Both our study and early literature indicate possible critical roles of mir-9 in inflammatory reaction in atherosclerosis. Mir-9 therefore can be an important potential target for intervening atherosclerosis-related inflammation, which is worth further investigation.
The activation of the NLRP3 inflammasome and the release of the mature form of IL-1β require two separate signals. "Signal one" activates a pattern recognition receptor, such as Toll-Like Receptor 4 (TLR4), which induces synthesis of pro-IL-1β. "Signal two" activates caspase-1, a protease that cleaves pro-IL-1β into a biologically active, secreted IL-1β [42] . OxLDL is the major proinflammatory stimulus of atherosclerosis and has been proposed to participate in both signal 1 and signal 2 for complete activation of the NLRP3 inflammasome, which is in line with our results [43] . We found that mir-9 could inhibit activation of NLRP3 inflammasome induced by oxLDL. Next, we used LPS and Alum as stimuli and further confirmed effects of mir-9 on the NLRP3 inflammasome. LPS is a classic and robust inflammation stimulus and has been reported to activate the NLRP3 inflammasome. Alum is an adjuvant commonly used in vaccine production and its role to stimulate NLRP3 dependent sterile inflammation has been recognized [28, 29] . Inhibiting the formation of the NLRP3 inflammasome has been reported to reduce myocardial injury after ischemia-reperfusion [16] . NLRP3 inflammasome inhibitor arglabin markedly reduced atherosclerosis-related inflammation and atherosclerotic lesions [44] . The size of atherosclerotic plaque was significantly reduced in ApoE -/-Casp-1 -/-double knockout mice compared with ApoE -/-single knockout mice [45] . Consistently, our finding provides new evidence regarding the crucial role of NLRP3 inflammasome activation in the pathogenesis of atherosclerosis.
MicroRNAs have been reported to regulate cellular functions through signaling pathways [46, 47] . The JAK/STAT signal pathway plays key roles in a variety of important cellular responses, such as inflammation, cell growth, metabolism, and gene transcription [45] . Our study found that JAK1/STAT1 was implicated in inflammatory reaction in oxLDLstimulated human THP-1 derived macrophages. In our study, anti-mir-9 treatment significantly increased JAK1 mRNA and protein expression, while pre-mir-9 treatment significantly decreased JAK1 mRNA and protein expression. Luciferase reporter assay further validated that JAK1 is a mir-9 target gene. Functional study discovered that JAK1 siRNA significantly decreased mRNA level and active protein expression of IL-1β and caspase-1, and decreased NLRP3 mRNA and protein expression, similar to pre-mir-9 mediated inhibition of NLRP3 inflammasome activation. Therefore we conclude that mir-9 could suppress activation of downstream NLRP3 inflammasome through its target gene JAK1. Moreover, we knocked down JAK1 by siRNA and at the same time inhibited mir-9 expression to further explore the effects of JAK1 in mir-9 induced suppression of the NLRP3 inflammasome. Compared to anti-mir-9 only, JAK1 siRNA plus anti-mir-9 significantly lowered the expression of IL-1β and NLRP3. The fact that mir-9 inhibition does not affect the function of JAK1 siRNA on downstream NLRP3 activation indicates that JAK1 is the crucial mediator of the effect of miR-9 on the expression of inflammasome components. It was reported that in mouse neural stem/progenitor cells (NPCs), JAK1 is one target gene of mir-9 identified by genetic approaches, which is consistent with our results [48] . They found that when mouse NPCs were transfected with miR-9, the protein expression of JAK1-STAT1/3 signaling components was reduced [48] . Zhang et al. reported that the JAK/STAT signaling pathway is involved in vascular smooth muscle cell (VSMC) proliferation and migration in early atherosclerosis [49] . Importantly, ruxolitinib (JAK1/JAK2 inhibitor) and tofacitinib (JAK3 inhibitor) have been approved to treat different autoimmune diseases, including psoriasis and rheumatoid arthritis [50] . However, Zhang et al. reported that miR-9 secreted by tumor cells could promote endothelial cell migration and angiogenesis by activating the JAK/STAT pathway [49] . The apparent discrepancies regarding the relation between miR-9 and the JAK/STAT pathway in these two studies may be due to different cell types and inflammatory status. As an important target of inflammation intervention, the roles of JAK1 in atherosclerosisrelated inflammatory reaction need more study in future research.
We found that STAT1 phosphorylation was inhibited by JAK1 siRNA, indicating that STAT1 was a downstream effector of JAK1 activation in oxLDL-stimulated human THP-1 derived macrophages. OxLDL has been proved to stimulate the binding activity of STAT1 in endothelial cells, fibroblasts and T lymphocytes [51, 52] . Activation of STAT1 is downstream of the LPS-induced TLR4/NF-κB signaling cascade in murine RAW 264.7 macrophages, which leads to expression of proinflammatory factors such as IL-6 and TNF-α [53] . Pharmacological inhibition of the JAK/STAT1 pathway or genetic deletion of STAT1 abrogated LPS-or type 1 IFN-induced HMGB1 cytoplasmic accumulation for subsequent release, which is a proinflammatory mediator during infection or sterile tissue injury [54] . Researchers also found that LPS could promote IL-1β and caspase-1 protein expression in STAT1 -/-BMDM from C57BL/6 mice, indicating mediation of STAT1 in LPS stimulated NLRP3 inflammasome activation [55] . Different roles of JAK and STAT family members in inflammation reaction might be due to varied cell sources and stimuli.
Continuous oxLDL stimulation can lead to cascade amplification of inflammatory reaction and persistent secretion of proinflammatory factors. NF-κB mediated signaling is the major pathway that modulates the pathogenesis of atherosclerotic plaques [39] . These findings support that miR-9 is highly associated with NF-κB related inflammation. Our work demonstrated that knockdown of JAK1 resulted in downregulation of NF-κB p65 in human THP-1 derived macrophage nuclei and reduction of NF-κB p-IκBα in cytoplasm, suggesting that NF-κB could be a pathway downstream of JAK1. NF-κB1 was previously shown to be one of mir-9's target genes. MiR-9 inhibits melanoma cell proliferation and migration through down-regulation of the NF-κB1-Snail1 pathway [40] . So it is possible for mir-9 to inhibit its downstream NF-κB signal transduction pathway through regulating JAK1. When oxLDL is added to human THP-1 derived macrophages, oxLDL could activate the JAK1/STAT1 and NF-κB signaling pathways, promote NLRP3 inflammasome activation, and release of proinflammatory cytokines. On the other hand, oxLDL could cause upregulation of mir-9, which in turn suppresses expression of its target gene JAK1. Meanwhile the NF-κB signaling pathway is blocked and eventually NLRP3 inflammasome activation and expression of NF-κB target genes such as IL-1β, IL-6 and IL-10 inflammatory factors are prohibited. The whole cellular responses make a negative feedback system. As a result, mir-9 can modulate inflammatory reaction in more than one ways, including direct and indirect effects on the NF-κB signaling pathway.
In addition, Xu et al. reported an interesting finding that miR-9 could target acetyl-CoA acetyltransferase 1 (ACAT1) to decrease the formation of foam cells from THP-1-derived macrophages [38] . Alternatively, miR-9 mediated decrease of foam cells formation may be explained as a direct result of inhibited NLRP3 activation and alleviated IL-1β release, or a changed NF-κB signaling pathway. Nevertheless, these points need further investigation.
Conclusion
Taken together, our data provides evidence that miR-9 inhibits NLRP3 inflammasome activation in oxLDL-stimulated human THP-1 derived macrophages and human primary peripheral blood monocytes. Our data also proves JAK1 as one target gene of miR-9, and the anti-inflammatory effect of miR-9 is at least partially through its interaction with the JAK1/STAT1 signaling pathway. Because the NLRP3 inflammasome plays a crucial role in atherosclerosis and inflammation, our findings shed novel insights into the regulatory effect of atherosclerosis-related inflammation and roles of miR-9, which maybe a potential therapeutic target for atherosclerosis.
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